Jafron Biomedical Co.,Ltd. (SHE:300529)
China · Delayed Price · Currency is CNY 19.69
+0.43 (2.23%)
Nov 13, 2026, 3:04 PM CST
Jafron Biomedical Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 854.93 | 2,516 | 1,725 | 2,810 | 2,559 | 2,319 |
Trading Asset Securities | 1,987 | 0.06 | 593.07 | - | - | 150.01 |
Cash & Short-Term Investments | 2,842 | 2,516 | 2,318 | 2,810 | 2,559 | 2,469 |
Cash Growth | 14.28% | 8.55% | -17.52% | 9.83% | 3.62% | 56.79% |
Accounts Receivable | 48.11 | 40.3 | 55.61 | 81.21 | 239.64 | 308.06 |
Other Receivables | 3.75 | 1.95 | 3.66 | 6.51 | 6.85 | 6.32 |
Receivables | 51.86 | 42.25 | 59.27 | 87.72 | 246.49 | 314.37 |
Inventory | 248.43 | 291.75 | 337.79 | 385 | 349.13 | 196.55 |
Prepaid Expenses | - | 0.69 | - | 0.32 | 14.55 | - |
Other Current Assets | 55.04 | 67.37 | 68.81 | 28.5 | 124.32 | 75.27 |
Total Current Assets | 3,197 | 2,918 | 2,784 | 3,312 | 3,293 | 3,056 |
Property, Plant & Equipment | 1,919 | 1,881 | 1,894 | 1,771 | 1,672 | 1,272 |
Long-Term Investments | 130.76 | 308.47 | 446.13 | 116.13 | 69.45 | 111.2 |
Goodwill | 7.01 | 7.01 | 7.01 | 12.21 | 37.81 | 44.07 |
Other Intangible Assets | 101.1 | 100.66 | 97.75 | 100.37 | 100.43 | 101.31 |
Long-Term Deferred Tax Assets | 40.47 | 41.81 | 34.97 | 30.35 | 36.49 | 26.54 |
Long-Term Deferred Charges | 75.72 | 86.65 | 87.19 | 94.87 | 59 | 35.95 |
Other Long-Term Assets | 35.13 | 64.95 | 32.35 | 107.03 | 148.22 | 162.91 |
Total Assets | 5,506 | 5,409 | 5,383 | 5,543 | 5,417 | 4,810 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Accounts Payable | 95.87 | 112.27 | 119.19 | 135.62 | 128.52 | 60.76 |
Accrued Expenses | 61.45 | 117.16 | 125.07 | 158.21 | 157.48 | 192.98 |
Short-Term Debt | 37.39 | 39.39 | 77.51 | 261.83 | 317.09 | - |
Current Portion of Long-Term Debt | 1,088 | 7.02 | 192.2 | 16.79 | - | - |
Current Portion of Leases | - | 1.58 | 1.83 | 3.83 | 4.73 | 3.17 |
Current Income Taxes Payable | 69.23 | 34.37 | 56.63 | 30.52 | 2.55 | 23.19 |
Current Unearned Revenue | 30.02 | 30.76 | 16.86 | 37.57 | 42.3 | 20.65 |
Other Current Liabilities | 65.4 | 159.54 | 177.51 | 185.03 | 64.52 | 85.51 |
Total Current Liabilities | 1,448 | 502.1 | 766.79 | 829.42 | 717.18 | 386.26 |
Long-Term Debt | 171.54 | 1,183 | 1,110 | 1,381 | 936.78 | 897.37 |
Long-Term Leases | 2.72 | 4.09 | 4.74 | 11.35 | 17.34 | 17.01 |
Long-Term Unearned Revenue | 207.53 | 228.64 | 144.95 | 151.78 | 151.66 | 125.08 |
Long-Term Deferred Tax Liabilities | 21.79 | 16.4 | 16.11 | 16.78 | 3.12 | 0.73 |
Other Long-Term Liabilities | 2.71 | 3.02 | 6 | - | - | - |
Total Liabilities | 1,854 | 1,938 | 2,049 | 2,390 | 1,826 | 1,426 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Common Stock | 798.61 | 798.61 | 798.61 | 807.56 | 807.71 | 805.5 |
Additional Paid-In Capital | 226.69 | 219.17 | 231.26 | 694.14 | 678.04 | 618 |
Retained Earnings | 3,003 | 2,832 | 2,918 | 2,408 | 2,507 | 2,336 |
Treasury Stock | -500.04 | -500.06 | -733.82 | -880.63 | -509.69 | -523.8 |
Comprehensive Income & Other | 122.49 | 122.49 | 119.69 | 118.63 | 91.7 | 123.14 |
Total Common Equity | 3,651 | 3,472 | 3,334 | 3,147 | 3,574 | 3,359 |
Minority Interest | 1.11 | -0.39 | 0.76 | 5.4 | 16.17 | 24.79 |
Shareholders' Equity | 3,652 | 3,471 | 3,335 | 3,153 | 3,590 | 3,384 |
Total Liabilities & Equity | 5,506 | 5,409 | 5,383 | 5,543 | 5,417 | 4,810 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Total Debt | 1,300 | 1,235 | 1,386 | 1,675 | 1,276 | 917.55 |
Net Cash (Debt) | 1,542 | 1,280 | 931.31 | 1,135 | 1,283 | 1,552 |
Net Cash Growth | 46.13% | 37.49% | -17.97% | -11.49% | -17.34% | -1.47% |
Net Cash Per Share | 1.98 | 1.66 | 1.19 | 1.43 | 1.62 | 1.93 |
Filing Date Shares Outstanding | 774.36 | 774.36 | 774.36 | 774.47 | 798.87 | 815.46 |
Total Common Shares Outstanding | 774.36 | 774.36 | 774.36 | 774.47 | 798.86 | 815.46 |
Working Capital | 1,750 | 2,416 | 2,017 | 2,482 | 2,576 | 2,669 |
Book Value Per Share | 4.72 | 4.48 | 4.31 | 4.06 | 4.47 | 4.12 |
Tangible Book Value | 3,543 | 3,364 | 3,229 | 3,035 | 3,436 | 3,213 |
Tangible Book Value Per Share | 4.58 | 4.34 | 4.17 | 3.92 | 4.30 | 3.94 |
Buildings | - | 1,297 | 1,296 | 1,260 | 890.61 | 812.74 |
Machinery | - | 823.61 | 764.58 | 678.23 | 514.6 | 304.98 |
Construction In Progress | - | 272.97 | 244.45 | 122.43 | 473.99 | 301.15 |